[A23-40] Risankizumab (Crohn disease) – Addendum to Commission A22-133
Last updated 15.06.2023
Project no.:
A23-40
Commission:
Commission awarded on 03.05.2023 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Digestion, metabolism and hormones
Indication:
Adults with moderately to severely active Crohn’s disease
Result of dossier assessment:
- who have had an inadequate response to, lost response to, or were intolerant to conventional therapy: added benefit not proven
- who have had an inadequate response to, lost response to, or were intolerant to a biologic therapy (TNF-alpha antagonist or integrin inhibitor or interleukin inhibitor): after addendum now hint of minor added benefit
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A22-133 | Risankizumab (Crohn’s disease) - Benefit assessment according to § 35a SGB V | Commission completed |
Federal Joint Committee (G-BA)
2023-06-15 A G-BA decision was published.